Primary splenic angiosarcoma: a case series of a rare oncological entity and diagnostic challenge
DOI:
https://doi.org/10.2340/1651-226X.2023.35412Keywords:
Angiosarcoma, Liver Failure, Primary Splenic Angiosarcoma, Splenic imaging, Splenic NeoplasmsAbstract
Background and purpose: Primary angiosarcoma of the spleen (PAS), an exceptionally rare and aggressive neoplasm with high metastatic risk (70%–85%), is frequently diagnosed in an advanced or metastatic stage. It presents diagnostic challenges due to its nonspecific symptomatology and resemblance to benign vascular lesions in various imaging modalities.
Patients and methods: This case series aims to clarify the diagnostic difficulties by comparing imaging characteristics (CT-scan, MRI, and [18F]FDG-PET/CT) as well as pathological findings of three PAS cases diagnosed in different stages of the diseases (localized, metastatic, and metastatic with organ failure). Furthermore, a brief review on diagnostic and therapeutic features is included.
Results and interpretation: We suggest [18F]FDG-PET/CT as a differentiating tool between benign and malignant splenic lesions and propose a flowchart of a diagnostic algorithm for PAS. For treatment, we advocate for early splenectomy and when systemic therapy is warranted, paclitaxel emerges as a viable first-line option. While it is crucial to acknowledge that further trial data is required to evaluate the efficacy of emerging treatment regimens, designing and conducting trials for PAS is challenging given its scarcity and aggressive behavior. Therefore case reporting remains important.
Downloads
References
Damouny M, Mansour S, Khuri S. Primary angiosarcoma of the spleen: an aggressive neoplasm. World J Oncol. 2022;13:337.
https://doi.org/10.14740/wjon1542 DOI: https://doi.org/10.14740/wjon1542
Hamid KS, Rodriguez JA, Lairmore TC. Primary splenic angiosarcoma. J Soc Laparoendosc Surg. 2010;14:431.
https://doi.org/10.4293/108680810X12924466006521 DOI: https://doi.org/10.4293/108680810X12924466006521
Fotiadis C, Georgopoulos I, Stoidis C, Patapis P. Primary tumors of the spleen. Int J Biomed Sci. 2009;5:85.
https://doi.org/10.59566/IJBS.2009.5085 DOI: https://doi.org/10.59566/IJBS.2009.5085
Montemayor P, Caggiano V. Primary hemangiosarcoma of the spleen associated with leukocytosis and abnormal spleen scan. Int Surg. 1980;65:369–73.
Chen X, Li H, Wang F, Liu H. Early detection and integral resection are keys to extend survival in patients suffered from primary angiosarcoma of the spleen: a care-compliant case report and literature review. Medicine. 2018;97:e9718.
https://doi.org/10.1097/MD.0000000000009718 DOI: https://doi.org/10.1097/MD.0000000000009718
Chen F, Jin H-F, Fan Y-H, Cai L-J, Zhang Z-Y, Lv B. Case report of primary splenic angiosarcoma with hepatic metastases. World J Gastroenterol. 2015;21:11199–204.
https://doi.org/10.3748/wjg.v21.i39.11199 DOI: https://doi.org/10.3748/wjg.v21.i39.11199
Barat M, Hoeffel C, Aissaoui M, et al. Focal splenic lesions: imaging spectrum of diseases on CT, MRI and PET/CT. Diagn Interven Imaging. 2021;102:501–13.
https://doi.org/10.1016/j.diii.2021.03.006 DOI: https://doi.org/10.1016/j.diii.2021.03.006
Ferreira BP, Rodler ET, Loggers ET, Pollack SM, Jones RL. Systemic therapy in primary angiosarcoma of the spleen. Rare Tumors. 2012;4:178–80.
https://doi.org/10.4081/rt.2012.e55 DOI: https://doi.org/10.4081/rt.2012.e55
Frontario SCN, Goldenberg-Sandau A, Roy D, Sandau R. Primary splenic angiosarcoma presenting as idiopathic thrombocytopenic purpura: a case report and review of the literature. Case Rep Surg. 2016;2016:4173060.
https://doi.org/10.1155/2016/4173060 DOI: https://doi.org/10.1155/2016/4173060
Rege SA, Takalkar Y, Singh A, Rijhsinghani AN. Primary splenic angiosarcoma: a diagnostic enigma. Int Surg J. 2020;7:2065–8.
https://doi.org/10.18203/2349-2902.isj20202438 DOI: https://doi.org/10.18203/2349-2902.isj20202438
Sözel H, Yılmaz F. Primary splenic angiosarcoma with liver metastasis caused by malign transformation of hemangioma: a case report and literature review. J Gastrointestinal Cancer. 2021;52:1086–89.
https://doi.org/10.1007/s12029-020-00550-5 DOI: https://doi.org/10.1007/s12029-020-00550-5
Despoina M, Dionysios D, Georgios A, Konstantinos S, Efstratios K, Adamantia Z-S. Primary angiosarcoma of the spleen: an oncological enigma. Case Rep Oncol Med. 2014;2014:193036.
https://doi.org/10.1155/2014/193036 DOI: https://doi.org/10.1155/2014/193036
Penel N, Bui BN, Bay J-O, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol. 2008;26:5269–74.
https://doi.org/10.1200/JCO.2008.17.3146 DOI: https://doi.org/10.1200/JCO.2008.17.3146
Stacchiotti S, Palassini E, Sanfilippo R, et al. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. Ann Oncol. 2012;23:501–8.
https://doi.org/10.1093/annonc/mdr066 DOI: https://doi.org/10.1093/annonc/mdr066
Phillips E, Jones RL, Huang P, Digklia A. Efficacy of eribulin in soft tissue sarcomas. Front Pharmacol. 2022;13:869754.
https://doi.org/10.3389/fphar.2022.869754 DOI: https://doi.org/10.3389/fphar.2022.869754
Jones RL, Ravi V, Brohl AS, et al. Efficacy and safety of TRC105 plus pazopanib vs pazopanib alone for treatment of patients with advanced angiosarcoma: a randomized clinical trial. JAMA Oncol. 2022;8:740–7.
https://doi.org/10.1001/jamaoncol.2021.3547 DOI: https://doi.org/10.1001/jamaoncol.2021.3547
Florou V, Rosenberg AE, Wieder E, et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J Immunother Cancer. 2019;7:1–8.
https://doi.org/10.1186/s40425-019-0689-7 DOI: https://doi.org/10.1186/s40425-019-0689-7
Blay J-Y, Chevret S, Le Cesne A, et al. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial. Lancet Oncol. 2023;24(8):892–902.
https://doi.org/10.1016/S1470-2045(23)00282-6 DOI: https://doi.org/10.1016/S1470-2045(23)00282-6
Grilley-Olson JE, Allred JB, Schuetze S, et al. A multicenter phase II study of cabozantinib+ nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902). Am Soc Clin Oncol. 2023;41(16_Suppl):11503.
https://doi.org/10.1200/JCO.2023.41.16_suppl.11503 DOI: https://doi.org/10.1200/JCO.2023.41.16_suppl.11503
Agulnik M, Okuno SH, Van Tine BA, et al. A phase II study of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas. Am Soc Clin Oncol. 2023;41(16_Suppl):11505.
https://doi.org/10.1200/JCO.2023.41.16_suppl.11505 DOI: https://doi.org/10.1200/JCO.2023.41.16_suppl.11505
Movva S, Avutu V, Chi P, et al. A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma. Am Soc Clin Oncol. 2023;41(16_Suppl):11517.
https://doi.org/10.1200/JCO.2023.41.16_suppl.11517 DOI: https://doi.org/10.1200/JCO.2023.41.16_suppl.11517
Painter CA, Jain E, Tomson BN, et al. The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat Med. 2020;26:181–7.
https://doi.org/10.1038/s41591-019-0749-z DOI: https://doi.org/10.1038/s41591-019-0749-z
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft tissue Sarcoma V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. [Accessed Nov 23, 2023]. Most recent and complete version of the guideline, see NCCN.org.
Gronchi A, Miah A, Dei Tos A, et al. Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 2021;32:1348–65.
https://doi.org/10.1016/j.annonc.2021.07.006 DOI: https://doi.org/10.1016/j.annonc.2021.07.006
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Iris Dirven, Philippe Leclercq, Lionel D'Hondt, Valentine Delmotte, Pierre Lefesvre, Hendrik Reynaert, Frederik Vandenbroucke, Magali Surmont
This work is licensed under a Creative Commons Attribution 4.0 International License.
